Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Dopamine receptor | Starlite/ChEMBL | References |
Rattus norvegicus | Adrenergic receptor alpha-2 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma japonicum | ko:K04135 adrenergic receptor, alpha 1a, putative | Dopamine receptor | 475 aa | 398 aa | 34.2 % |
Echinococcus multilocularis | serotonin receptor | Adrenergic receptor alpha-2 | 450 aa | 426 aa | 31.9 % |
Echinococcus granulosus | biogenic amine 5HT receptor | Adrenergic receptor alpha-2 | 450 aa | 423 aa | 31.7 % |
Loa Loa (eye worm) | TYRA-2 protein | Adrenergic receptor alpha-2 | 450 aa | 488 aa | 23.8 % |
Echinococcus multilocularis | alpha 1A adrenergic receptor | Adrenergic receptor alpha-2 | 450 aa | 478 aa | 20.7 % |
Echinococcus granulosus | alpha 1A adrenergic receptor | Adrenergic receptor alpha-2 | 450 aa | 476 aa | 21.0 % |
Schistosoma japonicum | ko:K04207 neuropeptide Y receptor Y5, putative | Adrenergic receptor alpha-2 | 450 aa | 378 aa | 20.9 % |
Schistosoma mansoni | biogenic amine (5HT) receptor | Adrenergic receptor alpha-2 | 450 aa | 433 aa | 27.9 % |
Echinococcus multilocularis | fmrfamide receptor | Adrenergic receptor alpha-2 | 450 aa | 366 aa | 19.9 % |
Schistosoma japonicum | ko:K04145 dopamine receptor D2, putative | Adrenergic receptor alpha-2 | 450 aa | 473 aa | 24.1 % |
Onchocerca volvulus | Adrenergic receptor alpha-2 | 450 aa | 420 aa | 19.8 % | |
Onchocerca volvulus | Adrenergic receptor alpha-2 | 450 aa | 467 aa | 25.1 % | |
Schistosoma mansoni | amine GPCR | Adrenergic receptor alpha-2 | 450 aa | 439 aa | 29.2 % |
Echinococcus multilocularis | neuropeptides capa receptor | Adrenergic receptor alpha-2 | 450 aa | 486 aa | 20.6 % |
Schistosoma japonicum | ko:K04136 adrenergic receptor, alpha 1b, putative | Dopamine receptor | 475 aa | 405 aa | 33.3 % |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 1.7 mg kg-1 | ED50 for induction of contralateral turning behaviour in 6-hydroxydopamine (6-OHDA) lesioned rats by ip administration. | ChEMBL. | 6094811 |
ED50 (functional) | = 1.7 mg kg-1 | ED50 for induction of contralateral turning behaviour in 6-hydroxydopamine (6-OHDA) lesioned rats by ip administration. | ChEMBL. | 6094811 |
IC50 (binding) | = 19 nM | Alpha-2 adrenergic receptor activity assessed in vitro for displacement of [3H]-clonidine from specific binding sites on rat striatal membranes | ChEMBL. | 6094811 |
IC50 (binding) | = 19 nM | Alpha-2 adrenergic receptor activity assessed in vitro for displacement of [3H]-clonidine from specific binding sites on rat striatal membranes | ChEMBL. | 6094811 |
IC50 (binding) | = 185 nM | Dopaminergic activity assessed in vitro for displacement of [3H]-apomorphine from specific binding sites on rat striatal membranes | ChEMBL. | 6094811 |
IC50 (binding) | = 185 nM | Dopaminergic activity assessed in vitro for displacement of [3H]-apomorphine from specific binding sites on rat striatal membranes | ChEMBL. | 6094811 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.